JP2024536088A5 - - Google Patents
Info
- Publication number
- JP2024536088A5 JP2024536088A5 JP2024518725A JP2024518725A JP2024536088A5 JP 2024536088 A5 JP2024536088 A5 JP 2024536088A5 JP 2024518725 A JP2024518725 A JP 2024518725A JP 2024518725 A JP2024518725 A JP 2024518725A JP 2024536088 A5 JP2024536088 A5 JP 2024536088A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- oligonucleotide
- target nucleic
- target
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248524P | 2021-09-26 | 2021-09-26 | |
| US63/248,524 | 2021-09-26 | ||
| US202263341391P | 2022-05-12 | 2022-05-12 | |
| US63/341,391 | 2022-05-12 | ||
| PCT/US2022/044767 WO2023049477A2 (en) | 2021-09-26 | 2022-09-26 | Compositions for editing mecp2 transcripts and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536088A JP2024536088A (ja) | 2024-10-04 |
| JP2024536088A5 true JP2024536088A5 (cg-RX-API-DMAC7.html) | 2025-10-06 |
Family
ID=85721202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518725A Pending JP2024536088A (ja) | 2021-09-26 | 2022-09-26 | Mecp2転写物を編集するための組成物及びその方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250135036A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4404942A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024536088A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022349529A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232965A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023049477A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| MA46427A (fr) | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| WO2018098264A1 (en) | 2016-11-23 | 2018-05-31 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| CN111108096A (zh) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | 寡核苷酸制备技术 |
| JP2021521140A (ja) | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2020241559A1 (en) | 2019-03-20 | 2021-11-11 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
| MX2021012981A (es) | 2019-04-25 | 2022-01-18 | Wave Life Sciences Ltd | Composiciones de oligonucleotido y metodos de uso de las mismas. |
| CN122555564A (zh) * | 2023-09-28 | 2026-08-11 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| WO2026055502A2 (en) * | 2024-09-05 | 2026-03-12 | Wave Life Sciences Ltd. | Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto |
| WO2026077951A1 (en) | 2024-10-07 | 2026-04-16 | Vico Therapeutics B.V. | Improved aon for rna editing |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190626A1 (en) * | 2002-04-09 | 2003-10-09 | Vasulinga Ravikumar | Phosphorothioate monoester modified oligomers |
| KR102678809B1 (ko) * | 2017-05-18 | 2024-06-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
| US11597744B2 (en) * | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| WO2019084062A1 (en) * | 2017-10-23 | 2019-05-02 | The Broad Institute, Inc. | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION |
| JP7679311B2 (ja) * | 2019-05-21 | 2025-05-19 | ビーム セラピューティクス インク. | プログラム可能塩基エディターシステムを用いた一塩基多型編集法 |
| CA3154768A1 (en) * | 2019-10-06 | 2021-04-15 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| EP4150076A1 (en) * | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
| JP2023548584A (ja) * | 2020-11-08 | 2023-11-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
-
2022
- 2022-09-26 EP EP22873722.7A patent/EP4404942A4/en active Pending
- 2022-09-26 JP JP2024518725A patent/JP2024536088A/ja active Pending
- 2022-09-26 CA CA3232965A patent/CA3232965A1/en active Pending
- 2022-09-26 US US18/695,348 patent/US20250135036A1/en active Pending
- 2022-09-26 WO PCT/US2022/044767 patent/WO2023049477A2/en not_active Ceased
- 2022-09-26 AU AU2022349529A patent/AU2022349529A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548584A5 (cg-RX-API-DMAC7.html) | ||
| US11673911B2 (en) | Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA) | |
| AU2014341879B2 (en) | Compositions and methods for controlling arthropod parasite and pest infestations | |
| JP2023535918A (ja) | Rna編集用のアンチセンスオリゴヌクレオチド | |
| JP2022519019A (ja) | オリゴヌクレオチド組成物及びその方法 | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| BR112021003224A2 (pt) | oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a | |
| HK1255699A1 (zh) | Kras表达的调节剂 | |
| TW201210611A (en) | Treatment of Nicotinamide Phosphoribosyltransferase (NAMPT) related diseases by inhibition of natural antisense transcript to NAMPT | |
| CN108410868A (zh) | Gcgr表达的反义调节 | |
| EP1141278B1 (en) | Therapeutic pde4d phosphodiesterase inhibitors | |
| CN105121452A (zh) | 三环核苷和由其制备的寡聚化合物 | |
| JP7463621B2 (ja) | ミトコンドリアアミドキシム還元成分1(marc1)発現を阻害するための組成物および方法 | |
| US20230235329A1 (en) | Antisense oligonucleotides (aso) for efficient and precise rna editing with endogenous adenosine deaminase acting on rna (adar) | |
| WO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| JP7560616B2 (ja) | 膜貫通型セリンプロテアーゼ6(tmprss6)発現を阻害するための組成物および方法 | |
| JP2021517826A (ja) | Gys2発現を阻害するための組成物及び方法 | |
| JP7497061B2 (ja) | Rna分子、キメラ型na分子、二本鎖rna分子、および二本鎖キメラ型na分子 | |
| JP5794559B2 (ja) | 間葉系細胞の分化を調節するための薬剤及びその利用 | |
| KR20230104880A (ko) | 올리고뉴클레오티드의 신경교세포로의 선택적 전달 | |
| US20210290653A1 (en) | Modulation of lnc05 expression | |
| WO2021177418A1 (ja) | Calm2のアンチセンスオリゴヌクレオチド | |
| CN115103911A (zh) | 修饰的异源核酸 | |
| AU2006345724B2 (en) | Compositions and methods for the treatment of muscle wasting | |
| WO2025026228A1 (zh) | Cfb抑制剂组合物及其应用 |